Mirvetuximab Soravtansine Shows Promising Topline Results in FRα-High, Platinum-Resistant Ovarian Cancer


The antibody-drug conjugate mirvetuximab soravtansine has shown promising response rates and a favorable toxicity profile in patients with folate receptor alpha-high, platinum-resistant ovarian cancer who have received previous treatment with bevacizumab.

Robert Coleman, MD

Robert Coleman, MD

The antibody-drug conjugate mirvetuximab soravtansine has shown promising response rates and a favorable toxicity profile in patients with folate receptor alpha (FRα)-high, platinum-resistant ovarian cancer who have received previous treatment with bevacizumab (Avastin), according to topline results from the phase 3 SORAYA trial (NCT04296890) released by ImmunoGen Inc.1

Results showed that the trial met its primary end point, with a confirmed objective response rate (ORR) of 32.4% (95% CI, 23.6%-42.2%) per investigator assessment, and 31.6% (95% CI, 22.4%-41.9%) per blinded independent central review (BICR). Both the investigator- and BICR-assessed ORR included 5 complete responses (CRs). Furthermore, the median duration of response (DOR) was 5.9 months (95% CI, 5.6-7.7).

“Despite advances in the platinum-sensitive setting, most patients with ovarian cancer eventually develop platinum-resistant disease, for which there are limited treatment options, especially for those patients who have previously received bevacizumab,” Robert Coleman, MD, co-principal investigator, and chief scientific officer of US Oncology Research, said in a press release. “Data from SORAYA have the potential to redefine the standard of care for patients with FRα-high platinum-resistant ovarian cancer, as this trial has demonstrated that mirvetuximab delivers clinically meaningful benefit in this setting, with significant and durable responses and a favorable tolerability profile.”

The SORAYA trial is a single-arm study examining mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer whose tumors express high levels of FRα. Patients enrolled on the study had received up to 3 prior treatment regimens, at least 1 of which included bevacizumab. Additionally, eligible patients had to be 18 years of age or older, have an ECOG performance status of 0 or 1, and have at least 1 lesion that met the definition of measurable disease by RECIST version 1.1 criteria.2

Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, or low-grade/borderline ovarian tumors were not able to enroll. Moreover, those with primary platinum-refractory disease were not eligible to participate.

The primary end point of the study is the confirmed investigator-assessed ORR, and key secondary end points included DOR, safety, progression-free survival, overall survival, and CA-125 response.

Furthermore, SORAYA was designed to rule out a 12% ORR. This is based on expected outcomes with single-agent chemotherapy from the phase 3 AURELIA trial (NCT00976911), which examined the combination of bevacizumab plus chemotherapy in patients with platinum-resistant ovarian cancer who had received up to 2 prior lines of therapy.

Among the 106 patients enrolled on the SORAYA study, the median number of prior lines of therapy was 3 (range, 1-4). Moreover, 51% of patients had received 3 prior lines of therapy, and 48% had received 1 or 2. All patients enrolled on the study received prior treatment with bevacizumab, and 48% of patients received prior treatment with a PARP inhibitor.

As of the data cutoff on November 16, 2021, the median follow-up was 8.1 months.

In terms of safety, mirvetuximab soravtansine was found to be well-tolerated, with a safety profile consistent with what has been observed in prior studies with the agent. Dose reductions due to treatment-related adverse effects (TRAEs) occurred in 19% of patients, dose delays due to TRAEs occurred in 32% of patients, and treatment discontinuations due to TRAEs occurred in 7% of patients. The most frequent TRAEs reported were blurred vision (41% all grade; 6% grade 3 or higher), keratopathy (35% all grade; 9% grade 3 or higher), and nausea (29% all grade; 0% grade 3 or higher).

“These data have the potential to be transformative for ovarian cancer patients and their physicians,” Ursula Matulonis, MD, co-principal investigator, chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School, said in a press release. “In the platinum-resistant setting and particularly in later-line treated patients, response rates with available therapy are in the single digits with significant toxicities. With an ORR above 30%, a duration of response of around six months, and a treatment-related discontinuation rate below 10%, mirvetuximab shows impressive activity and tolerability for patients with platinum-resistant ovarian cancer. If approved, mirvetuximab will become a critical therapeutic option for patients with FRα-high ovarian cancer.”

Submission of a biologics license application for mirvetuximab soravtansine in this patient population remains on track for the first quarter of 2022.


  1. ImmunoGen announces positive top-line results from pivotal SORAYA trial of mirvetuximab soravtansine in ovarian cancer. News release. ImmunoGen Inc. November 30, 2021. Accessed November 30, 2021. https://bit.ly/3E9vmfw
  2. A study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (SORAYA). clinicaltrials.gov. Updated May 27, 2021. Accessed November 30, 2021. https://www.clinicaltrials.gov/ct2/show/NCT04296890
Related Videos
Emil Lou, MD, PhD, FACP
Amma Asare, MD, PhD
Laura J. Chambers, DO
Casey M. Cosgrove, MD
Vaidehi Mujumdar, MD
Erin Crane, MD, MPH
Núria Agustí Garcia, MD
Yang Yang Hartwich, PhD
Gottfried Konecny, MD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse